MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Thermo Fisher Scientific Inc

Geschlossen

BrancheGesundheitswesen

469.72 -3.98

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

468.06

Max

487.64

Schlüsselkennzahlen

By Trading Economics

Einkommen

194M

1.8B

Verkäufe

795M

11B

KGV

Branchendurchschnitt

30.121

63.778

EPS

6.1

Dividendenrendite

0.35

Gewinnspanne

16.007

Angestellte

125,000

EBITDA

377M

3B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+36.36% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.35%

2.39%

Nächstes Ergebnis

23. Apr. 2025

Nächste Dividendenausschüttung

15. Apr. 2025

Nächstes Ex-Dividendendatum

13. Juni 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-40B

189B

Vorheriger Eröffnungskurs

473.7

Vorheriger Schlusskurs

469.72

Nachrichtenstimmung

By Acuity

32%

68%

93 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Thermo Fisher Scientific Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Feb. 2025, 14:05 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher Scientific to Acquire Solventum's Filtration Unit, Confirming WSJ Report

30. Jan. 2025, 11:43 UTC

Ergebnisse

Thermo Fisher Scientific Profit, Revenue Rose in 4Q

23. Okt. 2024, 10:43 UTC

Ergebnisse

Thermo Fisher Raises Floor of Earnings Target After Steady 3Q Sales

25. Feb. 2025, 14:09 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher Strikes Deal for Solventum's Filtration Unit -- WSJ

25. Feb. 2025, 13:41 UTC

Akquisitionen, Fusionen, Übernahmen

Solventum: Transaction Is Expected to Be Completed by End of 2025 >SOLV

25. Feb. 2025, 13:40 UTC

Akquisitionen, Fusionen, Übernahmen

Solventum Expects Estimated $3.4 B in Net Proceeds >SOLV

25. Feb. 2025, 13:40 UTC

Akquisitionen, Fusionen, Übernahmen

Solventum: Deal Strengthens Balance Sheet With Proceeds to Be Used Primarily for Debt Paydown >SOLV

25. Feb. 2025, 13:40 UTC

Akquisitionen, Fusionen, Übernahmen

Solventum Expects Deal to Be Neutral to 2025 EPS >SOLV

25. Feb. 2025, 13:40 UTC

Akquisitionen, Fusionen, Übernahmen

Solventum: Deal Accelerates Business Transformation and Sharpens Focus on Strategic Areas for Growth

25. Feb. 2025, 13:39 UTC

Akquisitionen, Fusionen, Übernahmen

Solventum Announces Sale of Its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

25. Feb. 2025, 13:33 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher: Solventum Business Generated About $1 Billion Revenue in 2024 >TMO

25. Feb. 2025, 13:32 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher to Buy Solventum Purification, Filtration Business for About $4.1 Billion Cash >TMO SOLV

25. Feb. 2025, 13:32 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher Scientific To Acquire Solventum's Purification And Filtration Business >TMO

24. Feb. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Thermo Fisher Scientific Nears Deal for Solventum's Purification and Filtration Business, Sources Say -- WSJ

24. Feb. 2025, 23:03 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Thermo Fisher Nears Deal for Solventum Filtration Unit -- WSJ

24. Feb. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Deal Could be Announced This Week, Sources Say -- WSJ

24. Feb. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Transaction Could Value Solventum Filtration Business Between $3.5B to $4B, Sources Say -- WSJ

30. Jan. 2025, 11:06 UTC

Ergebnisse

Thermo Fisher: In a Great Position to Deliver Excellent Performance in 2025 >TMO

30. Jan. 2025, 11:05 UTC

Ergebnisse

Thermo Fisher: Will Provide 2025 Fincl Guidance During Earnings Conference Call Thursday Morning >TMO

30. Jan. 2025, 11:00 UTC

Ergebnisse

Thermo Fisher 4Q Rev $11.4B >TMO

30. Jan. 2025, 11:00 UTC

Ergebnisse

Thermo Fisher 4Q EPS $4.78 >TMO

30. Jan. 2025, 11:00 UTC

Ergebnisse

Thermo Fisher 4Q Core Organic Revenue Up 5% >TMO

30. Jan. 2025, 11:00 UTC

Ergebnisse

Thermo Fisher 4Q Net $1.83B >TMO

30. Jan. 2025, 11:00 UTC

Ergebnisse

Thermo Fisher 4Q Adj EPS $6.10 >TMO

16. Dez. 2024, 22:03 UTC

Top News

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

23. Okt. 2024, 10:02 UTC

Ergebnisse

Thermo Fisher Had Seen 2024 Adjusted EPS $21.29-$22.07 >TMO

23. Okt. 2024, 10:02 UTC

Ergebnisse

Thermo Fisher Backs 2024 View of Rev $42.4B-$43.3B >TMO

23. Okt. 2024, 10:00 UTC

Ergebnisse

Thermo Fisher 3Q Core Organic Revenue 0% >TMO

23. Okt. 2024, 10:00 UTC

Ergebnisse

Thermo Fisher 3Q EPS $4.25 >TMO

23. Okt. 2024, 10:00 UTC

Ergebnisse

Thermo Fisher 3Q Adj EPS $5.28 >TMO

Peer-Vergleich

Kursveränderung

Thermo Fisher Scientific Inc Prognose

Kursziel

By TipRanks

36.36% Vorteil

12-Monats-Prognose

Durchschnitt 666.88 USD  36.36%

Hoch 715 USD

Tief 570 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Thermo Fisher Scientific Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

14

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

481.21 / 513.42Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

93 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar